Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25241917 | 0.86 | KDM4E (0.46) | KDM4EHSD17B10NLRP3GAATP53 | |
| SCHEMBL21677367 | 0.84 | NLRP3 (0.57) | KDM4EHSD17B10NLRP3GAATP53 | |
| SCHEMBL25771199 | 0.84 | KDM4E (0.44) | KDM4EHSD17B10NLRP3GAATP53 | |
| SCHEMBL25244370 | 0.83 | KDM4E (0.43) | KDM4EHSD17B10NLRP3GAATP53 | |
| SCHEMBL25291090 | 0.78 | HSD17B10 (0.39) | KDM4EHSD17B10NLRP3CYP2C19CYP1A2 | |
| SCHEMBL30194142 | 0.77 | NLRP3 (0.49) | KDM4EHSD17B10NLRP3TP53THRB | |
| SCHEMBL25771182 | 0.77 | NLRP3 (0.45) | HSD17B10NLRP3TP53THRBPOLB | |
| SCHEMBL30193839 | 0.76 | NLRP3 (0.44) | HSD17B10NLRP3TP53THRBPOLB | |
| SCHEMBL30193791 | 0.75 | NLRP3 (0.51) | NLRP3TP53THRBPOLB | |
| SCHEMBL25771179 | 0.74 | NLRP3 (0.41) | NLRP3THRBPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203064-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF NLRP3 | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230203064-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF NLRP3 | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230203064-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF NLRP3 | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| EP-4139312-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF NLRP3 | JANSSEN Pharmaceutica NV (BE) | 2023-03-01 | — | — | EP | disclosed |
| WO-2021214284-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF NLRP3 | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203064-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF NLRP3 | NLRP3, NLRP1, NOD1 | KDM4E 3915/4885HSD17B10 373/4885NLRP3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.